Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 28Leukemia, Lymphocytic, Chronic, B-Cell 14Myelodysplastic Syndromes 6Waldenstrom Macroglobulinemia 5Lymphoma, B-Cell, Marginal Zone 5Burkitt Lymphoma 5Lymphoma, Mantle-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Recurrence 2Neoplasms 2Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hematologic Neoplasms 2Blast Crisis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Follicular 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 5Whole-Body Irradiation 3Specimen Handling 3Injections 3CPX-351 3Blood Specimen Collection 3venetoclax 2luspatercept 2ivosidenib 2fludarabine phosphate 2fludarabine 2decitabine and cedazuridine drug combination 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Liposomes 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Filgrastim 2Daunorubicin 2Cyclosporine 2Cyclophosphamide 2Busulfan 2Biopsy 2Azacitidine 2tocilizumab 1selinexor 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × venetoclax × 30 days × Clear all
NCT05554406 2026-06-05

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡